Kestra Medical Technologies (KMTS) plans sale of 3,980 vested shares via Form 144

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. has a planned sale of common stock reported on Form 144. The filing covers 3,980 shares of common stock to be sold through Merrill Lynch, with an indicated value of $90,560.62 and a date of July 30, 2026 on NASDAQ.

The securities to be sold arose from the vesting of performance share unit awards on July 17, 2026, which were granted as part of the issuer’s equity compensation plan.

Key Figures

Shares to be sold: 3,980 shares of common stock Indicated value: $90,560.62 Proposed sale date: 07/30/2026 +1 more

4 metrics

Shares to be sold 3,980 shares of common stock Securities information section for proposed NASDAQ sale

Indicated value $90,560.62 Value associated with 3,980 common shares in Form 144

Proposed sale date 07/30/2026 Date tied to NASDAQ sale entry in securities information

Award vesting date 07/17/2026 Vesting date for performance share unit awards

Key Terms

Form 144, performance share unit awards, equity compensation plan

3 terms

Form 144 regulatory

"144: Securities Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

performance share unit awards financial

"Vesting of performance share unit awards"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:31 PM Accepted by SEC EDGAR 07/30/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What does Kestra Medical Technologies (KMTS) disclose in this Form 144?

Kestra Medical Technologies discloses a planned sale of 3,980 shares of common stock under Form 144, to be sold through Merrill Lynch with an indicated value of $90,560.62 on NASDAQ dated July 30, 2026.

How many Kestra Medical Technologies (KMTS) shares are covered by the planned sale?

The Form 144 covers a proposed sale of 3,980 shares of common stock. These shares are associated with previously granted performance share unit awards that vested on July 17, 2026 under the company’s equity compensation plan.

What is the approximate value of the Kestra Medical Technologies (KMTS) shares to be sold?

The filing lists an indicated value of $90,560.62 for the 3,980 common shares to be sold. This value appears in the securities information section associated with the proposed NASDAQ sale dated July 30, 2026.

When did the underlying awards for Kestra Medical Technologies (KMTS) shares vest?

The underlying performance share unit awards vested on July 17, 2026. The Form 144 states that the common stock to be sold resulted from the vesting of performance share unit awards granted under the issuer’s equity compensation plan.

How were the Kestra Medical Technologies (KMTS) shares to be sold originally granted?

The shares were granted as part of an issuer equity compensation plan. The Form 144 notes that the common stock arises from performance share unit awards granted under this plan, which vested on July 17, 2026 before the planned sale.

Through which broker will the Kestra Medical Technologies (KMTS) shares be sold?

The Form 144 lists Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281, as the broker for the proposed sale of 3,980 shares of Kestra Medical Technologies common stock on NASDAQ dated July 30, 2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	3980	90560.62	58602497	07/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			3980	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)